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Abstract
Inhibitors of histone acetyltransferases (HATs) are perceived to treat diseases like cancer,
neurodegeneration, and AIDS. On the basis of previous studies, we hypothesized that Cys1438 in
the substrate binding site could be targeted by Δ12-prostaglandin J2 (Δ12-PGJ2), a cyclopentenone
prostaglandin (CyPG) derived from PGD2. We demonstrate here the ability of CyPGs to inhibit
p300 HAT-dependent acetylation of histone H3. A cell-based assay system clearly showed that the
α,β-unsaturation in the cyclopentenone ring of Δ12-PGJ2 was crucial for the inhibitory activity,
while the 9,10-dihydro-15-deoxy- Δ12,14-PGJ2, which lacks the electrophilic carbon (at carbon 9),
was ineffective. Molecular docking studies suggested that Δ12-PGJ2 places the electrophilic
carbon in the cyclopentenone ring well within the vicinity of Cys1438 of p300 to form a covalent
Michael adduct. Site-directed mutagenesis of the p300 HAT domain, peptide competition assay
involving p300 wild type and mutant peptides, followed by mass spectrometric analysis confirmed
the covalent interaction of Δ12-PGJ2 with Cys1438. Using biotinylated derivatives of Δ12-PGJ2 and
9,10-dihydro-15-deoxy- Δ12,14-PGJ2, we demonstrate the covalent interaction of Δ12-PGJ2 with
the p300 HAT domain, but not the latter. In agreement with the in vitro filter binding assay,
CyPGs were also found to inhibit H3 histone acetylation in cell-based assays. In addition, Δ12-
PGJ2 also inhibited the acetylation of the HIV-1 Tat by recombinant p300 in in vitro assays. This
study demonstrates, for the first time, that Δ12-PGJ2 inhibits p300 through Michael addition,
where α,β-unsaturated carbonyl function is absolutely required for the inhibitory activity.
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The action of cyclooxygenase (COX) enzymes on arachidonic acid, followed by
isomerization of the product PGH2 by hematopoietic PGD synthase (H-PGDS) or lipocalin
PGDS (L-PGDS) leads to the formation of PGD2, which undergoes dehydration to form
PGJ2, Δ12-PGJ2, and 15d-PGJ2.1 Because the latter set of metabolites have a conserved
cyclopentenone structure, these molecules are commonly referred to as CyPGs of the J2
class. These CyPGs are implicated in a wide variety of diverse functions, such as anti-
inflammatory, antiviral, antitumor, and cytoprotective effects via multiple mechanisms,
including the modulation of transcription factors such as NF-κB, Nrf-2, and PPARγ.2–8
Recently, we have demonstrated the essential role of selenoproteins in the expression of H-
PGDS leading to enhanced production of CyPGs.3 Interestingly, CyPGs interact covalently
with the nucleophilic Cys thiolate anion in proteins via the two electrophilic carbons at
positions 9 and 13.9–12 CyPGs form Michael adducts with nucleophiles such as the free
sulfhydryl group of Cys residues located in reduced glutathione (GSH) or many cellular
proteins, including thioredoxin, p50, Ras, p53, Keap-1, IKK2, and HIV-1 Tat.4,7,9,13–19 As a
result, modification of functionally important sulfhydryl groups in many proteins often
results in the modulation of their biological activities, leading to changes in the transcription
of several downstream gene targets.20
The DNA is packaged as chromatin in the nucleus of eukaryotes by both histone and
nonhistone proteins.21 Chromatin plays a pivotal role in transcription, DNA repair, and
replication.22,23 The basic unit of chromatin is the nucleosome, which is composed of
dimers of histones H2A, H2B, H3, and H4 around which 147 base pairs of DNA are
wrapped. The N-terminal tails of histones are exposed to the surface of the nucleosome,
which serve as the main sites for post-translational modifications. Among the different post-
translational modifications, reversible acetylation of histones plays an important role in
maintaining the structure of the chromatin.24,25 Therefore, histone acetylation plays an
essential role in epigenetic regulation. Histone acetyltransferases (HATs) refers to the class
of enzymes that catalyze the acetylation reaction, which transfers the acetyl group from
acetyl-CoA to the amino tail of histones and other proteins at specific lysine residues. Thus,
HATs are also referred to as lysine acetyltransferases (KATs). These enzymes and the
associated acetylation events have been implicated in a wide variety of physiological and
diseases like neurodegeneration, cancer, HIV-AIDS, and inflammation.26–29 Histone
acetylation is catalyzed by five different classes of HATs.30 Among them, the best studied
are p300 (also referred to as KAT3B) and its close analogue CBP (KAT3A).
Histone acetyltransferase p300 is involved in various cellular events, and its dysfunction is
linked to diseases like cancer.27 The increasing evidence of p300 HAT activity with cancer
causation and progression has made it to be targeted for the development of anticancer
therapeutics. Many of the inhibitors of these enzymes are peptide conjugates of CoA or
natural products and their derivatives.31–36 All these inhibitors provide a valuable tool for
analyzing the structure and function of these enzymes, although their potential for
development as clinical drug candidates still remains to be determined. However, given the
presence of Cys1438 in the substrate-binding site of p300 HAT domain that is critical in the
binding and stabilization of the substrate, we hypothesized that CyPGs are likely to target
this reactive Cys residue to inhibit the enzymatic activity of p300.37,38
In this study, we describe the ability of CyPGs to inhibit the activity of p300 in vitro and in
hepatocytes and macrophages. Our studies comparing the various CyPGs clearly evolve an
intriguing structure–activity relationship in PGs indicating the importance of the α,β-
unsaturated carbonyl function to be essential to inhibit the activity of p300 HAT. Molecular
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modeling studies, showing the interaction of biotinylated derivatives of CyPGs, further lend
credence to the idea that these reactive metabolites could impact epigenetic and gene
regulatory functions. Here, we also provide data to translate these findings to address the




The following PGs were purchased from Cayman Chemicals (MI, USA): Δ12-PGJ2, PGJ2,
PGD2, PGE2, PGK2, PGA2, PGB2, 9,10-dihydro-15d-PGJ2, and 13,14-dihydro-PGD2. All
compounds were of high purity and were used without further purification. [Acetyl-1-14C]-
CoA (60 mCi/mmol) was purchased from Perkin-Elmer Life Sciences (Waltham, MA).
Whatman P81 chromatography paper was obtained from Fisher Scientific Chemicals
(Pittsburgh, PA). HeLa core histones and antibodies that recognize specific acetylated lysine
residues in histone H3 (K9 and K14) and total histone H3 were obtained from Active motif
(Carlsbad, CA). GST-tagged recombinant p300 HAT domain corresponding to amino acids
1066–1707 of human p300 expressed in E.coli was obtained from Millipore (Billerica, MA).
Similarly, GST-tagged recombinant PCAF (p300/CBP-associated factor; 165 amino acids;
corresponding to residues 503–651) was purchased from Cayman Chemicals. HIV-1 Tat
protein was expressed in a bacterial system and purified using His-affinity chromatography
in our laboratory as described previously.14
Histone Acetyltransferase Assay
HAT assays were performed as described previously with some modifications.39 p300 or
PCAF were incubated with or without molar equivalents of PGs at room temperature for 3 h.
Then 0.8 μg of highly purified HeLa core histones were incubated in HAT assay buffer (50
mM Tris–HCl, pH 8.0, 1 mM PMSF, 0.1 mM EDTA, and 10% v/v glycerol) at 30 °C for 10
min, with or without p300 or PCAF (PG treated and untreated). The reaction mixture was
incubated for an additional 10 min upon addition of 0.25 μL of 60 mCi/mmol [14C] acetyl
CoA in a total volume of 30 μL. The reaction mixture was then blotted onto a P-81 filter
paper (Whatman) and washed with carbonate buffer (0.2 M Na2CO3 and 0.2 M NaHCO3),
and counts were recorded in a Beckman liquid scintillation counter. All assays were
performed in triplicate.
Viability Assay
All PGs were tested for toxicity at 10 μM. The viability of cells after various treatments was
estimated in terms of their ability to reduce the dye (3,4,5- dimethyl thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (CCK-8 kit, Dojindo, Gaithersburg, MD) to blue purple
formazan crystals, as per the manufacturer's instructions.
Analysis of Histone Acetylation in HepG2, RAW264.7, and U1/HIV-1 Cells
Human liver hepatoblastoma (HepG2) cells (ATCC; HB-8065) (1 × 106 cells per 60 mm2
dish) were seeded overnight and treated with various PGs at indicated concentrations or
vehicle (DMSO, 0.1% v/v) the following day for 24 h. Murine macrophage-like cells
(RAW264.7; ATCC) were cultured in Dulbecco's minimum essential medium containing D-
glucose (5 mM; Invitrogen), sodium selenite (250 nM; Sigma Aldrich), and FBS (5%, v/v;
ATCC). These cells were stimulated with E. coli LPS (50 ng/mL) for 2 h and cultured in the
above media in the presence or absence of indomethacin (10 μM) or HQL-79 (25 μM;
Cayman), which inhibit COX-1/2 and H-PGDS, respectively. Total histones were extracted
from vehicle and compound-treated cells as described previously.35 Equal amounts of the
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protein samples were run on a 12% (%T) SDS–polyacrylamide gel and the separated
histones were electro-transferred onto a nitrocellulose membrane. The membranes were
probed with specific anti-(K9/K14) acetyl H3 and total anti-H3 C-terminal antibodies
(Active motif). Detection was performed with goat antirabbit secondary antibody (Thermo
Pierce, Rockford, IL), and bands were visualized using the ECL detection system (Thermo
Pierce). U1/HIV-1 cells, obtained from the NIH AIDS Research and Reference Reagent
Program, were cultured in RPMI 1640 supplemented with FBS (10% v/v) and stimulated for
12 h with 20 ng/mL phorbol myristic acid (PMA; Sigma) and subsequently treated with
vehicle or Δ12-PGJ2 for 24 and 48 h. Histones were isolated from the cells, and their
acetylation status was analyzed as described earlier.
Site-Directed Mutagenesis of the p300 HAT Domain
The p300 HAT cDNA (region corresponding to amino acid residues 1066 to 1707) was
cloned from HEK293T cDNA using the following primers: forward, 5′
TACCGTCAGGATCCAGAATCCCTTCCC 3′, and reverse, 5′
TTTCTCCATTTTGTGGTCATGGTTTTTAGTGTTATAGC 3′. EcoRI and EagI restriction
endonuclease sites (in bold) were added to the p300 cDNA using the primers forward, 5′
GAATTCTACCGTCAGGATCCAGAATCC 3′, and reverse, 5′
CCATAGCGGCCGCTTTCTCCATTTTGTGGTCATGG 3′. The p300 cDNA was
subcloned into EcoRI and EagI sites in the pET41c(+) vector (Novagen). Such a pET41c-
p300 plasmid was used as the template to generate the p300C1438A mutant using the
Stratagene site-directed mutagenesis kit according to the manufacturer's instructions. The
primers used for the mutagenesis were as follows: forward, 5′
GCATATTTGGGCAGCACCACCAAGTGAG 3′; and reverse, 5′
CCTCACTTGGTGGTGCTGCCCAAATATG 3′ (underlined codons in bold represent the
mutated Cys residue).
Reaction of the p300 HAT Domain and Biotinylated PGs
The ability of these compounds to bind the p300 HAT domain was examined in vitro. Δ12-
PGJ2 and 9,10-dihydro-15-deoxy-Δ12,14-PGJ2 were biotinylated using EZ-link-5-
(biotinamido)pentylamine (Thermo Pierce) in the presence of EDC (1-ethyl-3-(3-
diaminomethylamino-propyl) carbodiimide hydrochloride) as the coupling agent as
described.14 Briefly, the biotinylated PGs were purified on a preparative silica gel 60
column (70–230 mesh; Sigma Chemicals, St. Louis, MO) developed with ethyl acetate
followed by elution with ethyl acetate/methanol (80:20). The eluates were run on a thin layer
chromatography using AL SILG/UV plates (Whatman, 250 μm layer; Kent, UK). Fractions
containing biotinylated PGs were pooled and confirmed by mass spectrometry (m/z of
645.44 and 627.78 for Δ12-PGJ2-biotinamide and 9,10-dihydro-15d-PGJ2-biotinamide,
respectively) and a dot blot probed with streptavidin-HRP. The p300 HAT domain (10
pmol/30 μL reaction volume), biotinylated Δ12-PGJ2 (10 pmol), and 9,10-dihydro-PGJ2 (10
pmol) were incubated in HAT assay buffer for 3 h (at 25 °C) with 10 μg of cell nuclear
extract from U937 monocytic cells. The latter was subjected to pull-down with neutravidin–
agarose beads followed by Western blot analysis by with GST antibody or neutravidin–HRP
conjugate to examine the interaction between p300 and Δ12-PGJ2.
Binding Studies with C1438A Mutant
BL21 cells were transformed with native pET41c-p300 or pET41c-p300C1438A plasmids.
The transformed cells were grown in Terrific Broth to log phase and induced with 1 mM
IPTG overnight. Then 0.2 nmol of the native or mutant p300 protein was bound to HisPur
resin (Pierce) according to the manufacturer's instructions. Δ12-PGJ2 biotinamide solution
(0.2 nmol) prepared in 1% DMSO (in 50 mM Tris-Cl, pH 8.0) was reacted with the resin-
bound protein for 3 h at room temperature on an end-to-end shaker. Following washes with
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50 mM Tris-Cl, pH 8.0, the resin was boiled with 1× SDS gel loading buffer. HisPur resin
alone, 0.2 nmol of Δ12-PGJ2 biotinamide solution bound to resin, native p300, and
p300C1438A protein bound to the resin were used as negative controls. The samples were
analyzed by Western immunoblotting with the indicated reagents.
Interaction of Δ12-PGJ2 with the p300 Peptide
The peptide sequences 1433GHIWACPPSEG and its mutant 1433GHIWAAPPSEG were
purchased from GenScript Inc. (Piscataway, NJ). The peptides (0.3 μM) and Δ12-PGJ2 (0.3
μM) were incubated for 3 h in HAT assay buffer, in a reaction volume of 30 μL. The
reactions were analyzed by infusion and using an LC-MS/MS system comprising Shimadzu
LC20AD UFLC pumps, a Luna phenyl-hexyl column (150 × 2 mm, 3 μm; Phenomenex),
and a ABI2000 triple quadruple mass spectrometer with an electrospray ionization probe set
to positive mode at 250 °C for the confirmation of the product ion peak. The solvent system
used was methanol/H2O (70:30), with 0.1% acetic acid, at a flow rate 0.15 mL/min.
Peptide Competition Assay
The peptides (10 pmol) were added to the p300 HAT domain (10 pmol) along with
biotinylated Δ12-PGJ2 (10 pmol and 20 pmol) for 3 h at 25 °C, in a reaction volume of 30 μL
followed by Western blot analysis with neutravidin-HRP or anti-GST.
p24 Quantitation
The U1/HIV-1 cell line was cultured in RPMI-1640 media (Cellgro) supplemented with
10% heat inactivated fetal calf serum (Hyclone), 2 mM L-glutamine (Invitrogen), penicillin
(0.5 units/mL), and streptomycin (0.5 μg/mL). The cells were stimulated with 20 ng/mL of
PMA for 12 h. Δ12-PGJ2 in DMSO (0.1% v/v) was added to the stimulated cells, and the
cultures were incubated at 37 °C for 24 and 48 h. Unstimulated cells were used as a negative
control. Culture supernatant was sampled every 24 h for p24 analysis. The quantity of p24 in
the samples was measured with a commercial kit following the manufacturer's instructions
(CosmoBio, Japan). All of the assays were performed in triplicate.
In Vitro Acetylation of HIV-1 Tat Protein by p300 HAT
Ten picomoles of the p300 HAT domain was incubated in the presence or absence of 30
pmol of Δ12-PGJ2 for 3 h at room temperature in 30 μL. This mixture was then incubated
with 350 pmol of His-tag labeled recombinant Tat (rTat) protein and 0.1 μCi of
[acetyl-1-14C] CoA for 1 h at room temperature. The rTat protein was subjected to pull-
down using HisPur resin, which was boiled, centrifuged, and the supernatant subjected to
scintillation counting.
Molecular Docking Studies
To develop a prospective pharmacophore for ligand interactions with the Cys1438 of p300
HAT domain, we applied a two-stage modeling protocol. First, we docked the following
three fragment species: (a) 4-allyl-5-methylenecyclopent-2-enone, (b) (4R,5R)-4-methyl-5-
vinylcyclopentane-1,3-dione, and (c) (R)-3-allyl-2-methylenecyclopentanone into p300-
HAT via the Surflex program, as guided by specifying a protomol construct based solely on
the position and character of Cys1438 (residue-based protomol generated automatically in
Surflex according to default parameters). Docking proceeded according to default parameter
settings with the exception that the number of initial starting conformations was increased to
20, and the number of requested poses was set to 50. From the resulting docking simulation,
the bound conformations were examined in order to find the top scoring pose that positioned
either a sp2 hybridized ring carbon or oxygen within 4 Å of the Cys sulfur; in each case,
either the very highest or the second highest scoring pose satisfied this criterion. The
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fragment poses selected in this first stage were then merged into a single MOL2 file to serve
as the base for a ligand-based protomol generation (performed automatically in Surflex
according to default parameters) for the second stage. In the second stage, PGJ2, Δ12-PGJ2,
PGK2, and 9,10-dihydro-15-deoxy-Δ12,14-PGJ2 were docked to p300-HAT via Surflex via
the above fragment-based protomol and according to the same docking protocol as described
in the first stage. Bound conformations were again examined to identify the top scoring pose
that positioned either an sp2 hybridized ring carbon or oxygen as described earlier. This
spatial orientation criterion was again satisfied either by the single top scoring pose (as was
the case for PGJ2, PGK2, and 9,10-dihydro-15-deoxy-Δ12,14-PGJ2) or by the second-best
pose (Δ12-PGJ2). Pose clustering analysis revealed that the single most populous
conformational family resolved for each ligand corresponded to poses satisfying the Cys1438
spatial proximity criterion, and in each case, more than half of all poses placed either the
ring oxygen or electrophilic carbon within a somewhat more lenient criterion of 5.0 Å
distance from the sulfur.
Results
Inhibition of p300 HAT Activity by CyPGs
In vitro p300 HAT assays using [acetyl-1-14C] CoA and HeLa core histones with the
recombinant p300 HAT domain that was preincubated with various concentrations (100
nM-5 μM) of PGs clearly indicated an interesting pattern. While PGD2, PGE2, PGK2, PGB2,
and PGA2 failed to inhibit the HAT activity of p300, Δ12-PGJ2 and PGJ2 (Δ13-PGJ2)
inhibited the activity of p300 significantly. The IC50 values with Δ12-PGJ2 and PGJ2 were
calculated to be ∼750 nM and >2 μM, respectively (Figure 1). Furthermore, Δ12-PGJ2 and
PGJ2, being positional isomers, showed differences in their reactivities toward the inhibition
of p300 activity. However, Δ12-PGJ2 failed to inhibit recombinant PCAF activity even at 5
μM (data not shown). PGD2, PGE2, PGK2, and 9,10-dihydro-15-deoxy-Δ12,14-PGJ2 lack an
unsaturation at carbon-9 and did not exhibit any inhibitory properties. It should also be noted
that PGD2, the precursor for CyPGs of the J2 class, did not affect HAT activity, while the
dehydration product (Δ12-PGJ2) was effective toward HAT p300 suggesting that metabolism
to CyPGs is essential for activity.
The ability of these PGs to inhibit cellular p300 HAT activity was tested in HepG2, a human
hepatocarcinoma cell line, where histones (H3 and H4) are known to be hyper
acetylated.36,40 As a preliminary screen, HepG2 cells were treated with 10 μM of each of the
PGs. No significant toxicities were observed (Supporting Information, Figure S1). As shown
in Figure 2, treatment with Δ12-PGJ2 and PGJ2 showed significant reduction in the histone
H3 acetylation level. (Figure 2A; lanes 2 and 3). PGA2 showed a nonsignificant decrease
(Figure 2A; lane 10). However, PGE2, PGB2, PGK2, 9,10-dihydro-15-deoxy-Δ12,14-PGJ2,
PGD2, and 13,14-dihydro-PGD2 were ineffective at inhibiting acetylation in these cells
(Figure 2A; lanes 4–9). On the basis of these results, it became clear that Δ12-PGJ2 appeared
to be a potent inhibitor of p300. Thus, we used Δ12-PGJ2 as a lead compound for further
studies. Treatment of HepG2 cells with increasing concentrations (0.5-10 μM) of Δ12-PGJ2
showed a dose-dependent inhibition of histone H3 K9/K14 acetylation, with more than 90%
inhibition at 10 μM of Δ12-PGJ2 compared to the DMSO control (Figure 3A; compare lane 1
vs lane 3). The IC50 was calculated to be ∼5 μM.
To address if endogenously produced CyPGs were capable of inhibiting HAT activity, we
used a murine macrophage (RAW264.7) cell model that has been shown by our laboratory
to produce high levels of CyPG when cultured in the presence of a fully expressed
selenoproteome.3,41 As shown in Figure 3C, treatment of such cells with either
indomethacin (10 μM) or HQL-79 (25 μM), which inhibit COX-1/2 and H-PGDS,
respectively, clearly demonstrated an increased acetylation of histone H3K9/K14 compared
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to that of the DMSO control. Treatment of RAW264.7 cells with indomethacin or HQL-79
did not show any effect on HDAC-1 expression (data not shown). These results provide
sufficient proof-of-concept that endogenous CyPG have the ability to modulate HAT
activity.
Δ12-PGJ2 Inhibits p300 by Michael Addition
On the basis of the differences in the ability of Δ12-PGJ2 and 9,10-dihydro-15-deoxy-Δ12,14-
PGJ2 to inhibit p300 activity, and the fact that the substrate-binding site of p300 contains a
Cys residue (aa 1438), we speculated that p300 perhaps covalently interacted with Δ12-
PGJ2. To examine the interaction of Δ12-PGJ2, biotinylated Δ12-PGJ2 and 9,10-dihydro-15-
deoxy-Δ12,14-PGJ2 were used. 9,10-Dihydro-15-deoxy-Δ12,14-PGJ2 was mainly used as a
control. The biotinylated compounds were incubated with the recombinant p300 HAT
domain for 3 h, and the binding of biotinylated derivatives of Δ12-PGJ2 or 9,10-dihydro-15-
deoxy-Δ12,14-PGJ2 to p300 was analyzed by SDS–PAGE under denaturing conditions
followed by Western blotting with neutravidin-HRP and GST. Figure 4A clearly indicates
the binding of Δ12-PGJ2 to p300; while 9,10-dihydro-derivative was ineffective. To further
address if this interaction was intact even in the presence of other proteins, nuclear extracts
from U937 human monocytic cells were mixed with recombinant p300 to which biotinylated
CyPGs were added. These samples were subjected to pull-down with neutravidin–agarose
beads overnight. The binding of p300 to biotinylated Δ12-PGJ2 or biotinylated 9,10-
dihydro-15-deoxy-Δ12,14-PGJ2 was analyzed by gel electrophoresis and immunoblotting
with anti-GST antibody (Figure 4A), followed by probing the same membrane with the
neutravidin–HRP conjugate (Figure 4A). The results in Figure 4A clearly demonstrate that
the presence or absence of nuclear proteins did not affect the interaction of biotinylated Δ12-
PGJ2 with p300, while biotinylated 9,10-dihydro-15-deoxy-Δ12,14-PGJ2 did not interact with
p300. Furthermore, in the above in vitro reaction, a peptide containing the reactive Cys1438
was coincubated with the p300 HAT domain and Δ12-PGJ2 at 1:1 and 1:2 molar ratios
(p300/peptide) for 3 h followed by immunoblotting with the neutravidin-HRP conjugate to
examine the biotinylation of p300. As expected, the peptide inhibited the interaction of Δ12-
PGJ2 with p300 at both 1:1 and 1:2 molar ratios (Figure 4B). Taken together, these results
strongly support the ability of Δ12-PGJ2 to interact with p300 by forming a covalent adduct.
Δ12-PGJ2 Interacts Covalently with Cys1438 in p300 HAT
Given the presence of Cys1438 in the active site of p300, we examined its role as a
nucleophilic acceptor for the binding of Δ12-PGJ2 in the following studies. First, the p300
peptide (GHIWACPPSEG) or mutant peptide lacking Cys (GHI-WAAPPSEG)
corresponding to amino acids 1433–1443 in p300 was incubated for 3 h with molar
equivalents of Δ12-PGJ2, and the complex was analyzed by LC-MS as well as by direct
infusion. As shown in Figure 5(A,B), the native peptide and the peptide-Δ12-PGJ2 adduct
could be separated by LC. An increase in the m/z of molecular ion of the peptide from
1153.2 to 1487.0 clearly indicated that the peptide interacted covalently with Δ12-PGJ2
(Figure 5C,D). Second, mutagenesis of Cys1438 to Ala in the substrate binding site of the
p300 HAT domain followed by in vitro binding studies with Δ12-PGJ2-biotinamide clearly
indicated that Cys1438 was indispensible for the covalent interaction of Δ12-PGJ2 with p300
(Figure 6A,B). Incubation of the mutant peptide with the p300 HAT domain and Δ12-PGJ2
demonstrated a clear lack of competition with p300 for Δ12-PGJ2 (Figure 5B). In addition,
incubation of the mutant peptide with Δ12-PGJ2 did not lead to a corresponding increase in
the molecular mass of the peptide.
To probe this interaction further, we utilized a molecular modeling approach using the
crystal structure of the HAT domain of p300 liganded to a synthetic inhibitor, lysyl-CoA,
reported recently.38 In order to gauge the propensity for PGs to bind to p300-HAT via
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precovalent conformations suitable for covalent reaction with binding site nucleophiles, we
examined the model generated from the crystal structure of p300-HAT for solvent-exposed
Cys residues within close proximity of the cocrystallized CoA ligand. Using this structure,
molecular modeling studies with different CyPGs were performed. As shown in Figure 7, all
of the PGs tested were seen to bind to p300 HAT. Of these, Δ12-PGJ2 was found to have the
strongest affinity for this putative covalent binding mode (Surflex score = 7.86), followed by
9,10-dihydro-15-deoxy-Δ12,14-PGJ2 (7.18), PGK2 (6.49), and 15d-PGJ2 (6.07). Further
analysis of the interaction between Δ12-PGJ2 and Cys1438 showed that the electrophilic
carbon-9 was positioned within 4 Å of the nucleophilic Cys-S− to facilitate the formation of
an adduct. 9,10-Dihydro-15-deoxy-Δ12,14-PGJ2 also snuggly fit into the substrate binding
site but was not capable of interacting with Cys1438 due to the lack of an electrophilic carbon
as shown in Figure 7A. Interestingly, the two hydrophobic tails of Δ12-PGJ2 were positioned
around the antiparallel β-sheets in p300 such that the electrophilic center at carbon-9 in the
cyclopentenone was placed in the vicinity of Cys1438 (Figure 7B–D). However, in the case
of PGA2, PGK2, and PGB2, which were ineffective in inhibiting H3 acetylation, the
positioning of the α,β-unsaturated reactive center was farther away from the Cys1438, thus
making them less likely to interact with the nucleophilic Cys-S− in the substrate binding site.
Taken together, these studies further provide support to the premise that Δ12-PGJ2
covalently interacts with p300 via the Cys1438 in the substrate-binding pocket of p300.
Δ12-PGJ2 Inhibits the Acetylation of HIV-1 Tat Protein by p300 HAT
It has been previously shown that the HIV Tat protein, which serves as a substrate for p300,
is acetylated at K50 and K51 and that this acetylation is important for its activity.42 To
examine if Δ12-PGJ2-dependent inhibition of p300 HAT activity had any effect on the
acetylation of Tat, the p300 HAT domain was incubated in the presence or absence of Δ12-
PGJ2 (1:3) for 3 h at room temperature. Recombinant Tat protein (His-tagged) and
[acetyl-1-14C] CoA were added to the p300 HAT-Δ12-PGJ2 complex, and the reaction
mixture was incubated for an additional 1 h at room temperature. rTat was subjected to pull-
down with HisPur resin and washed with PBS, and the beads were boiled with SDS-PAGE
gel loading buffer. Radioactivity in the supernatant was counted by scintillation counting.
As expected, rTat was acetylated by the p300 HAT domain that was not preincubated with
Δ12-PGJ2 (Figure 8A). However, the p300 HAT domain that was alkylated (carbonylated)
by Δ12-PGJ2 exhibited significantly low acetylation activity toward rTat. It was observed
that the acetylation of rTat by p300 was inhibited upon incubation of the HAT domain with
Δ12-PGJ2 (Figure 8A). Furthermore, we extended the analysis to examine the effect of Δ12-
PGJ2 treatment of U1/HIV cells (human monocytic cells chronically infected with HIV-1)
that were previously stimulated with PMA to activate the expression of the integrated
provirus. Treatment of such cells with Δ12-PGJ2 (2 μM) for 24 and 48 h clearly showed
differences in the levels of acetylation of H3 (at K9 and K14), as a function of time (Figure
8B). While the decrease in Ac-H3 on day 1 was not substantial (Figure 8B; compare lane 1
vs 2), the decrease in Ac-H3 on day 2 post treatment was greatly decreased (Figure 8B;
compare lane 3 vs 4). Treatment with 2 μM of Δ12-PGJ2 for 2 days did not cause any
toxicity in these cells (Supporting Information, Figure S2). Levels of p24, a component of
the HIV virus capsid in the supernatant of these PMA-stimulated cells also showed a
significant (∼70%) decrease upon treatment with Δ12-PGJ2, particularly at day 2 post-
treatment (Figure 8C). Taken together, these studies indicate that Δ12-PGJ2 is a potent
inhibitor of p300-dependent acetylation of Tat as well as H3 in HIV-infected cells, which
contributes, in part, to the reduction in HIV proviral expression.
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Many studies have documented an important role for CyPGs as key modulators of gene
expression by their ability to modify proteins involved in signaling transduction cascades,
chromatin dynamics, and transcription factors.40 Such an interaction with proteins, mainly
through Cys thiols, contributes to the pleiotropic effects of these reactive metabolites of
PGD2. Although beneficial effects of CyPGs are reported in experimental models of
inflammation, CyPGs are also known to promote proliferation and angiogenesis.43,44 Thus,
given the ability of these molecules to act in a context-specific, cell-specific, and
concentration-dependent manner, it is very likely that CyPGs may impact many vital cellular
processes that continue to unfold. In continuation of our quest into the characterization of
the CyPG interactome, we report here, for the first time, that Δ12-PGJ2, a metabolic end
product of arachidonic acid-derived PGD2, inhibits the enzymatic activity of p300 HAT.
Site-directed mutagenesis and peptide competition experiments further indicated that the
inhibition of p300 HAT activity by Δ12-PGJ2 occurred via the alkylation of Cys1438 in the
substrate-binding site. This is in contrast to the role of 15d-PGJ2, a dehydrated product of
Δ12-PGJ2, which has been shown to inactivate HATs through their insolubilization in
HepG2 cells; while Δ12-PGJ2 did not affect the stability of p300.45 Furthermore, 15d-PGJ2
also has been shown to inhibit mammalian class I HDACs by covalent binding to two
conserved Cys.46 Thus, given these effects of 15d-PGJ2, we have excluded this molecule
from the current studies.
Although the molecular basis of epigenetic regulation of gene expression is complex, there
is now a clear understanding that HATs, such as p300 and its paralogue CREB-binding
protein (CBP), modify the unstructured N-termini of histones (called “histone tails”), and
are generally correlated with transcriptional competence and diverse biological processes.
However, the ability of p300 to impact the function of many histone and nonhistone proteins
by acetylation has further invigorated the search for specific inhibitors of this key
transferase.47 The “relaxed” substrate specificity of p300 is attributed due to the lack of a
deep substrate-binding pocket that potentially prohibits the formation of a stable ternary
complex between the enzyme and the two cosubstrates.38 These studies reporting the ability
of Δ12-PGJ2 to inhibit the activity of p300 by a unique mechanism involving the
nucleophilic Cys in the substrate binding site opens a new area in the field of eicosanoid-
dependent regulation of gene expression, particularly in inflammation and HIV biology.
The ability of CyPGs to interact with nucleophiles, particularly Cys thiols (thiolate anion),
provides the basis for the biological effects. However, this depends largely on whether cells
can produce such high amounts of free CyPGs in cells. One might speculate that localized
concentrations of CyPGs in the high nanomolar range may be possible given the fact that
COX isozymes, which are membrane bound, functionally couple with downstream PGDS
isozymes, which are mostly cytosolic, to produce PGD2 that undergoes nonenzymatic
dehydration and isomerization to form PGJ2, Δ12-PGJ2, and 15d-PGJ2. In fact, recent reports
from our laboratory have demonstrated the role of micronutrient selenium (Se), in the form
of selenoproteins, to shunt pathways of arachidonic acid metabolism from PGE2 to PGD2
metabolites in macrophages.3,41 Our macrophage model is capable of producing relatively
high concentrations of Δ12-PGJ2. As a result, the production of high levels of extracellular
Δ12-PGJ2 relative to its dehydration product, 15d-PGJ2, was observed in macrophages
supplemented with Se, which is not surprising given the thermodynamic constraints
associated with the final dehydration of Δ12-PGJ2 to 15d-PGJ2.3,48 Studies with such
Seenriched macrophages demonstrate the inhibition of acetylation of H3K9/14 by
indomethacin and HQL-79, when compared to the vehicle control, suggesting the
endogenous production of CyPG to inhibit HAT activity. Further studies to correlate the
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effects of enhanced cellular production of CyPGs on acetylation of histone and nonhistone
proteins are currently underway in our laboratory and will be reported in the near future.
Our results show an interesting structure–function correlation wherein Δ12-PGJ2 and its
positional isomer, PGJ2 (Δ13-PGJ2), differ in their ability to inhibit p300, with Δ12-PGJ2
being more reactive than Δ13-PGJ2. Comparing the two isomers, the presence of a
conjugated diene structure following tautomeric rearrangement of electrons within the
cyclopentenone ring possibly makes the carbon 9 more electrophilic; while in the case of
PGJ2, due to the presence of an unsaturation at carbon 13, a relatively less electrophilic
nature of carbon 9 may help explain the differences in their inhibitory activities.9 The
differences in the reactivity of CyPGs isomers are reminiscent of their interaction with GSH
as reported by Atsmon et al.9 On the basis of the molecular modeling studies, all PGs tested,
including 9,10-dihydro-15d-PGJ2, seem to enter the substrate-binding site in p300, where
the positioning of the electrophilic carbon 9 in the close vicinity of Cys1438 appears to be
critical for the inhibitory activity. Along the same lines, PGA2 and PGB2, although CyPGs,
were ineffective as inhibitors of p300, possibly owing to the position of its electrophilic
carbon. Similarly, PGK2 that lacks an alkylidenecyclopentenone structure did not inhibit the
enzyme even though the cyclopentanedione ring was likely to orient π orbitals favorably for
S nucleophilic attack. This is in contrast to that in HDACs, where even an unrelated
electrophile like 4-hydroxynonenal binds to the Cys residues.46 Thus, it appears that binding
and positioning of the electrophilic carbon 9 in CyPGs to the nucleophilic Cys1438
determines the selectivity. Experiments showing the abrogation of interaction of p300 HAT
domain with Δ12-PGJ2 upon incubation of p300 peptide containing Cys1438 further suggest
that accessibility of the Cys residue plays an equally important role, which is reminiscent of
the interaction of CyPGs with specific Cys residues in thioredoxin, GSTP1-1, ubiquitin
carboxyl-terminal hydrolase-1, and H-Ras.18,19,49,50 Along these lines, we have previously
described the ability of CyPGs to interact with Cys thiols in HIV-1 Tat, and here, we
demonstrate that the consequence of inhibition of p300 has a major effect on the activation
of Tat and HIV replication in general (Figure 8B,C), accompanied by a decrease in H3
acetylation levels.14
On the basis of the discussion above, it is clear that the mere presence of an α,β-unsaturated
carbonyl structure is not sufficient to inhibit p300 activity. That said, natural products like
curcumin, plumbagin, and garcinol, which also contain α,β-unsaturated carbonyl
functionalities, inhibit p300 HAT activity through a different mechanism involving a weak
hydrogen bonding with Lys1358.31–33,35,36 Furthermore, oxo-containing metabolites of lipid
mediators, such as 17-oxo-RvD1, which are formed endogenously from docosahexaenoic
acid, could also modulate HAT activity by forming Michael adducts.51 Thus, it would be
interesting to examine the ability of all these (natural) compounds to interact with Cys1438 to
better appreciate the stereoselectivity as well as define their role in modulating gene
expression. Interestingly, our results are in agreement with those reported with plumbagin
with regard to the increased specificity toward p300 rather than PCAF.36 This is not
surprising since the active site of PCAF lacks the presence of a nucleophilic residue in the
form of a conserved Cys648 residue that is too far from the active site.52
In summary, we have identified an oxidized fatty acid metabolite as a p300 HAT inhibitor.
Our data supports the selective inhibition of p300 HAT activity only by certain CyPGs,
based on their ability to interact covalently with Cys1438, a key residue that is pivotal for the
binding of substrates, to form a Michael adduct. Although the observed IC50 of Δ12-PGJ2
toward p300 is higher than the concentration of Δ12-PGJ2 produced in the macrophage
model, the cellular data may not correlate entirely with the in vitro analysis due to many
factors, such as the use of the p300 HAT domain in isolation that could alter the structure of
this domain in the absence of other interaction partners, lowering the reactivity and
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accessibility of the Cys thiol. Needless to say, these studies need to be evaluated in the light
of tissue and cell-specific toxicity of CyPGs. Our studies demonstrating the targeting of
p300 with Δ12-PGJ2 on the acetylation of Tat opens a new window of opportunity to
regulate proviral transcriptional replication. Such studies are likely to further expand to
examine the effect of inhibition of p300 by Δ12-PGJ2 on many other transcription factors to
provide a better understanding of the role of this class of endogenous metabolites in areas
such as resolution of inflammation, where CyPGs are already known to facilitate the
process. Although preliminary studies on the inability of Δ12-PGJ2 to inhibit PCAF suggests
some level of selectivity, further studies are required to examine the effect of these CyPGs
on other classes of HAT enzymes, where a similar mechanism may be followed.53,54
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structure of PGs along with their inhibitory activity toward p300. Each compound was
tested for the inhibitory activity of p300 from 0.1 to 5 μM in in vitro assays, and IC50 values
were calculated. The average of three independent assays is shown. NA, no activity.
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Inhibition of H3 acetylation by PGs in HepG2 cells. (A) HepG2 cells were treated as
indicated for 24 h; histones were isolated from DMSO treated cells (lane 1); PGs-treated
cells at 10 μM concentration (lanes 2–10). The histone acetylation was analyzed by
immunoblotting using acetylated H3 antibody and histone H3 as a loading control. (B)
Densitometric analysis of total H3 versus acetylated H3. Mean ± SEM of three independent
assays shown. *, p < 0.00005. 13,14-DH-PGD2 and 9,10-DH-PGJ2 represent 13,14-
dihydro-15-keto-PGD2 and 9,10-dihydro-15d-PGJ2, respectively.
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Δ12-PGJ2 inhibits p300 acetylation of H3 in HepG2 and RAW264.7 cells. (A) HepG2 cells
were treated with various concentrations of Δ12-PGJ2 for 24 h and histones were isolated
from untreated cells (lane 1), DMSO treated cells (lane 2), Δ12-PGJ2-treated cells at 10 μM
(lane 3), 5 μM (lane 4), 1 μM (lane 5), and 500 nM (lane 6). The histone acetylation was
probed by immunoblotting using acetylated H3 antibody and histone H3 as a loading
control. (B) Densitometry analysis of total H3 versus acetylated H3. Mean ± SEM values of
three independent experiments are shown. *, p < 0.05; **, p < 0.005; ***, p < 0.0005. (C)
RAW264.7 cells cultured in DMEM containing 250 nM sodium selenite was treated with
DMSO, indomethacin (10 μM), or HQL-79 (25 μM) for 3 days following a 2 h LPS (50 ng/
mL) exposure. Histones were isolated and acetylation of H3 at K9 and K14 was examined
by immunoblotting. Representative of n = 3 is shown.
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Δ12-PGJ2 forms a covalent adduct with p300. (A) Left panel (Western blot): p300-GST was
incubated with and without biotinylated PGs in an in vitro reaction. The reactions were
analyzed by immunoblotting. Right panel (pull-down with neutravidin agarose): p300-GST
was mixed with nuclear extracts (NE) from U937 monocytic cells and reacted with or
without biotinylated PGs. These samples were subjected to pull-down with neutravidin–
agarose beads and analyzed by immunoblotting. Representative of n = 2 shown. (B) Peptide
competition assay. p300 only (lane 1), p300 and biotinylated Δ12-PGJ2 (lane 2), p300,
biotinylated Δ12-PGJ2 and peptide (1:1 = p300: peptide; lane 3), p300 and biotinylated Δ12-
PGJ2 (lane 4), p300, biotinylated Δ12-PGJ2 and peptide (1:2 = p300/peptide; lane 5). As a
loading control, the blots were probed with GST. Representative of n = 2 is shown.
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LC-MS analysis of p300 peptide conjugated with Δ12-PGJ2. The peptides (0.3 μM) and Δ12-
PGJ2 (0.3 μM) were incubated for 3 h in HAT assay buffer, in a reaction volume of 30 μL.
The reactions were analyzed by LC-MS/MS as described in the Experimental Procedures
section. The solvent system used was methanol/H2O/acetic acid (70:30:0.1) at a flow rate
0.15 mL/min. Panels A and B represent p300 peptide only and p300 peptide incubated with
Δ12-PGJ2, respectively. Panels C and D represent MS of the “peptide peak” and “adduct
peak” from the TIC in panels A and B, respectively.
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Site-directed mutagenesis of p300 HAT domain. (A) Interaction of p300C1438A protein
with Δ12-PGJ2. p300 wild type or C1438A mutant proteins were incubated with Δ12-PGJ2
biotinamide followed by SDS–PAGE analysis and Western blotting with neutravidin-HRP
or GST. Lanes 1–6 represent, buffer alone, Δ12-PGJ2 biotinamide alone, native p300 only,
p300-C1438A alone, native p300 + Δ12-PGJ2 biotinamide, and p300 C1438A + Δ12-PGJ2
biotinamide, respectively. (B) Peptide competition assay. In the above reaction, wild type or
mutant peptides were included followed by Western blotting. Lanes 1–4 represent p300
only, p300 + biotinylated Δ12-PGJ2 (1:1 molar ratio), p300 incubated with biotinylated Δ12-
PGJ2 and mutant peptide, and p300 incubated with biotinylated Δ12-PGJ2 and wild type
peptide, respectively. Since native p300 and p300C1438A were expressed with a GST tag,
blots were reprobed with anti-GST to confirm near uniform loading. Representative of n = 2
is shown. (C) Mass spectrometric evaluation (by direct infusion) of the interaction of mutant
peptide before and after incubation with Δ12-PGJ2.
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Molecular modeling of CyPGs to p300 HAT domain. (A) Predicted precovalent conformers
for four PGs in the CoA binding site of p300-HAT. Connolly surface color scheme:
hydrophobic = yellow; weakly polar alkyl = white; polar O, N, H = red, blue, and cyan
respectively; and the surface of the putatively reactive sulfur on Cys1438 = orange for
contrast. Ligands are rendered as sticks with CPK colors, except for carbon atoms, which are
shown as follows: cocrystallized CoA analogue = white; PGJ2 = green; Δ12-PGJ2 = brown;
PGK2 = violet; and 9,10-dihydro-15d-PGJ2 = black. (B) Docking study of PGs to the p300
HAT domain. (C) Orientation of the cyclopentenone ring of PGs toward Cys1438. (D)
Formation of the covalent bond between carbon 9 of CyPG with Cys1438 is shown as a
dotted line.
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Δ12-PGJ2 inhibits p300-dependent on the acetylation of HIV-1 Tat. (A) rTat was incubated
with Δ12-PGJ2 treated and untreated p300 HAT domain and [acetyl-1-14C] CoA. rTat was
pulled down using HisPur resin. The resin was washed with PBS, boiled with SDS–PAGE
gel loading buffer, and subjected to scintillation counting. Negative and positive controls
correspond to p300 + [acetyl-1-14C] CoA and p300 + [acetyl-1-14C] CoA + rTat,
respectively. Mean ± SEM values of three independent experiments are shown. (B) U1/HIV
cells were stimulated and treated with Δ12-PGJ2 at 2 μM for 24 and 48 h. Day 1, DMSO
treated (lane 1), 2 μM Δ12-PGJ2 (lane 2); day 2, DMSO treated (lane 3), 2 μM Δ12-PGJ2
(lane 4). Representative blots of n = 3 are shown. (C) Δ12-PGJ2 decreases p24 levels in
chronically HIV-1 infected human monocytes. The viral structural protein p24, secreted into
the culture medium was estimated by using an antigen-capture assay. The difference
between cells treated with the control and 2 μM concentration of Δ12-PGJ2 was found to be
statistically significant. Error bars represent the SEM of three independent experiments. *, p
< 0.05; **, p < 0.005. US, unstimulated cells; Veh, vehicle (DMSO).
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